Actuate Therapeutics (ACTU) Stock Overview

A clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. More details

ACTU fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings have grown 1.2% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

Volatile share price over the past 3 months compared to the US market

+ 1 more risk

ACTU Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW487,274 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

487,274 investors already sharing narratives

View all narratives

Actuate Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Actuate Therapeutics
Historical stock prices
Current Share Price	US$1.23
52 Week High	US$9.22
52 Week Low	US$1.16
Beta	0
1 Month Change	-38.81%
3 Month Change	-28.49%
1 Year Change	-80.10%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-85.71%

Recent updates

Seeking Alpha • Jul 29

Actuate: Elraglusib Continues To Deliver And Next Catalyst Is FDA Type B Meeting

Summary Actuate Therapeutics' elraglusib combo showed strong phase 2 results in 1st-line metastatic pancreatic cancer patients, improving survival and reducing disease progression. A major catalyst is the upcoming FDA Type B pre-NDA meeting, which could allow a faster regulatory path to U.S. marketing approval or require a phase 3 trial first. Despite promising data, significant financial risks and potential dilution remain, as current cash likely won't last past Q2 2025. I rate ACTU as 'Hold' until FDA feedback clarifies the approval path; a positive outcome from it could warrant a 'Buy' upgrade. Read the full article on Seeking Alpha

Seeking Alpha • Mar 26

Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer

Summary Actuate Therapeutics' lead drug, elraglusib, shows promise in early trials for pancreatic cancer but faces challenges like solubility issues and financial instability. The company's phase 2 trial showed improved survival rates with elraglusib, but the control arm underperformed, raising questions about future phase 3 results. ACTU's financials are concerning, with only $8.6 million in cash and a high burn rate, making future funding uncertain. Despite interesting early data, the significant risks and financial challenges make ACTU a risky investment at this time. Read the full article on Seeking Alpha

Analysis Article • Feb 12

Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

	ACTU	US Biotechs	US Market
7D	-19.1%	3.4%	-0.4%
1Y	-80.1%	37.9%	18.4%

Return vs Industry: ACTU underperformed the US Biotechs industry which returned 37.9% over the past year.

Return vs Market: ACTU underperformed the US Market which returned 18.4% over the past year.

Price Volatility

Is ACTU's price volatile compared to industry and market?
ACTU volatility
ACTU Average Weekly Movement	16.0%
Biotechs Industry Average Movement	10.5%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.2%

Stable Share Price: ACTU's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ACTU's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2015	12	Dan Schmitt	actuatetherapeutics.com

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias.

Actuate Therapeutics, Inc. Fundamentals Summary

How do Actuate Therapeutics's earnings and revenue compare to its market cap?
ACTU fundamental statistics
Market cap	US$31.82m
Earnings (TTM)	-US$21.54m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.4x

P/E Ratio

Is ACTU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACTU income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$21.54m
Earnings	-US$21.54m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.90
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ACTU perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/09 23:04
End of Day Share Price	2026/07/09 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Actuate Therapeutics, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Mayank Mamtani	B. Riley Securities, Inc.
Gum-Ming Lowe	Craig-Hallum Capital Group LLC
Swayampakula Ramakanth	H.C. Wainwright & Co.

Actuate Therapeutics (ACTU) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Actuate Therapeutics, Inc. Competitors

Aligos Therapeutics

Senti Biosciences Holdings

Genenta Science

Lite Strategy

Price History & Performance

Recent News & Updates

Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000 Index

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Actuate Therapeutics, Inc. Announces Appointment of Martin Huber as an Independent Director, Effective May 6, 2026

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Actuate Therapeutics, Inc., Annual General Meeting, May 21, 2026

Actuate Therapeutics, Inc. Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into A Phase 1/2 Clinical Program in Refractory Cancers

Recent updates

Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000 Index

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Actuate Therapeutics, Inc. Announces Appointment of Martin Huber as an Independent Director, Effective May 6, 2026

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Actuate Therapeutics, Inc., Annual General Meeting, May 21, 2026

Actuate Therapeutics, Inc. Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into A Phase 1/2 Clinical Program in Refractory Cancers

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-To-Treat Refractory Pediatric Cancers

Actuate Therapeutics, Inc. Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma

Actuate Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA over the Coming Months

Actuate Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.000006 million.

Actuate Therapeutics, Inc. to Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Actuate: Elraglusib Continues To Deliver And Next Catalyst Is FDA Type B Meeting

Actuate Therapeutics, Inc. Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-To-Treat Pediatric Sarcomas

Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000E Value Index

Actuate Therapeutics, Inc. announced that it expects to receive $4.665479 million in funding

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

Actuate Therapeutics, Inc. Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Actuate Therapeutics, Inc. Shares Highlights from Kol Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics, Inc. Presents Topline Elraglusib Phase 2 Data At Asco 2025 Annual Meeting

Actuate Therapeutics, Inc. Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer

Actuate Therapeutics, Inc. Announces Completion of Patient Enrollment in Ongoing Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan for Undreated Metastatic Pancreatic Pancreatic Ductal Adenocarcinoma

Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Invest In Growth?

Actuate Therapeutics, Inc., Annual General Meeting, May 22, 2025

Actuate Therapeutics, Inc. Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

Actuate Therapeutics, Inc. Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics, Inc. Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

Actuate Therapeutics, Inc. has completed an IPO in the amount of $22.4 million.